PTC to ask for FDA approval of vatiquinone for FA by year’s end
PTC Therapeutics says it’s planning, this December, to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy vatiquinone — which has been tested in pediatric patients as well as adults — as a treatment for Friedreich’s ataxia (FA). “We look forward to submitting…